BACKGROUND Two phase 3 trials (UNCOVER-2 and UNCOVER-3) showed that at 12 weeks of treatment, ixekizumab, a monoclonal antibody against interleukin-17A, was superior to placebo and etanercept in the treatment of moderate-to-severe psoriasis. We report the 60-week data from the UNCOVER-2 and UNCOVER-3 trials, as well as 12-week and 60-week data from a third phase 3 trial, UNCOVER-1. METHODS We randomly assigned 1296 patients in the UNCOVER-1 trial, 1224 patients in the UNCOVER-2 trial, and 1346 patients in the UNCOVER-3 trial to receive subcutaneous injections of placebo (placebo group), 80 mg of ixekizumab every 2 weeks after a starting dose of 160 mg (2-wk dosing group), or 80 mg of ixekizumab every 4 weeks after a starting dose of 160 mg (4-wk dosing group). Additional cohorts in the UNCOVER-2 and UNCOVER-3 trials were randomly assigned to receive 50 mg of etanercept twice weekly. At week 12 in the UNCOVER-3 trial, the patients entered a long-term extension period during which they received 80 mg of ixekizumab every 4 weeks through week 60; at week 12 in the UNCOVER-1 and UNCOVER-2 trials, the patients who had a response to ixekizumab (defined as a static Physicians Global Assessment [sPGA] score of 0 [clear] or 1 [minimal psoriasis]) were randomly reassigned to receive placebo, 80 mg of ixekizumab every 4 weeks, or 80 mg of ixekizumab every 12 weeks through week 60. Coprimary end points were the percentage of patients who had a score on the sPGA of 0 or 1 and a 75% or greater reduction from baseline in Psoriasis Area and Severity Index (PASI 75) at week 12. RESULTS In the UNCOVER-1 trial, at week 12, the patients had better responses to ixekizumab than to placebo; in the 2-wk dosing group, 81.8% had an sPGA score of 0 or 1 and 89.1% had a PASI 75 response; in the 4-wk dosing group, the respective rates were 76.4% and 82.6%; and in the placebo group, the rates were 3.2% and 3.9% (P<0.001 for all comparisons of ixekizumab with placebo). In the UNCOVER-1 and UNCOVER-2 trials, among the patients who were randomly reassigned at week 12 to receive 80 mg of ixekizumab every 4 weeks, 80 mg of ixekizumab every 12 weeks, or placebo, an sPGA score of 0 or 1 was maintained by 73.8%, 39.0%, and 7.0% of the patients, respectively. Patients in the UNCOVER-3 trial received continuous treatment of ixekizumab from weeks 0 through 60, and at week 60, at least 73% had an sPGA score of 0 or 1 and at least 80% had a PASI 75 response. Adverse events reported during ixekizumab use included neutropenia, candidal infections, and inflammatory bowel disease. CONCLUSIONS In three phase 3 trials involving patients with psoriasis, ixekizumab was effective through 60 weeks of treatment. As with any treatment, the benefits need to be weighed against the risks of adverse events. The efficacy and safety of ixekizumab beyond 60 weeks of treatment are not yet known.

Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis

ROMANELLI, MARCO;
2016-01-01

Abstract

BACKGROUND Two phase 3 trials (UNCOVER-2 and UNCOVER-3) showed that at 12 weeks of treatment, ixekizumab, a monoclonal antibody against interleukin-17A, was superior to placebo and etanercept in the treatment of moderate-to-severe psoriasis. We report the 60-week data from the UNCOVER-2 and UNCOVER-3 trials, as well as 12-week and 60-week data from a third phase 3 trial, UNCOVER-1. METHODS We randomly assigned 1296 patients in the UNCOVER-1 trial, 1224 patients in the UNCOVER-2 trial, and 1346 patients in the UNCOVER-3 trial to receive subcutaneous injections of placebo (placebo group), 80 mg of ixekizumab every 2 weeks after a starting dose of 160 mg (2-wk dosing group), or 80 mg of ixekizumab every 4 weeks after a starting dose of 160 mg (4-wk dosing group). Additional cohorts in the UNCOVER-2 and UNCOVER-3 trials were randomly assigned to receive 50 mg of etanercept twice weekly. At week 12 in the UNCOVER-3 trial, the patients entered a long-term extension period during which they received 80 mg of ixekizumab every 4 weeks through week 60; at week 12 in the UNCOVER-1 and UNCOVER-2 trials, the patients who had a response to ixekizumab (defined as a static Physicians Global Assessment [sPGA] score of 0 [clear] or 1 [minimal psoriasis]) were randomly reassigned to receive placebo, 80 mg of ixekizumab every 4 weeks, or 80 mg of ixekizumab every 12 weeks through week 60. Coprimary end points were the percentage of patients who had a score on the sPGA of 0 or 1 and a 75% or greater reduction from baseline in Psoriasis Area and Severity Index (PASI 75) at week 12. RESULTS In the UNCOVER-1 trial, at week 12, the patients had better responses to ixekizumab than to placebo; in the 2-wk dosing group, 81.8% had an sPGA score of 0 or 1 and 89.1% had a PASI 75 response; in the 4-wk dosing group, the respective rates were 76.4% and 82.6%; and in the placebo group, the rates were 3.2% and 3.9% (P<0.001 for all comparisons of ixekizumab with placebo). In the UNCOVER-1 and UNCOVER-2 trials, among the patients who were randomly reassigned at week 12 to receive 80 mg of ixekizumab every 4 weeks, 80 mg of ixekizumab every 12 weeks, or placebo, an sPGA score of 0 or 1 was maintained by 73.8%, 39.0%, and 7.0% of the patients, respectively. Patients in the UNCOVER-3 trial received continuous treatment of ixekizumab from weeks 0 through 60, and at week 60, at least 73% had an sPGA score of 0 or 1 and at least 80% had a PASI 75 response. Adverse events reported during ixekizumab use included neutropenia, candidal infections, and inflammatory bowel disease. CONCLUSIONS In three phase 3 trials involving patients with psoriasis, ixekizumab was effective through 60 weeks of treatment. As with any treatment, the benefits need to be weighed against the risks of adverse events. The efficacy and safety of ixekizumab beyond 60 weeks of treatment are not yet known.
2016
Gordon, K. B; Blauvelt, A.; Papp, K. A.; Langley, R. G.; Luger, T.; Ohtsuki, M.; Reich, K.; Amato, D.; Ball, S. G.; Braun, D. K.; Cameron, G. S.; Erickson, J.; Konrad, R. J.; Muram, T. M.; Nickoloff, B. J.; Osuntokun, O. O.; Secrest, R. J.; Zhao, F.; Mallbris, L.; Leonardi, C. L.; Uncover, 1 Study Group: Holly Hake Harris; Robert T., Matheson; Michael, Bukhalo; John H., Tu; Jeffrey J., Crowley; Kimberly K., Grande; Adnan, Nasir; Boni Elizabeth, Elewski; James Alan, Solomon; Liebhild, Stratmann; Claudia, Buettner; Thomas Peter, Dirschka; Margrit Ruth, Simon; Jens, Ulrich; Christine, Grigat; Mathias, Augustin; Andrei, Khariouzov; Gerhard, Sattler; Hans Michael, Ockenfels; Fredrick Richard, Behringer; Hector, Wiltz; Francisco, Flores; Kevin D., Kuettel; Ira Hughes, Thorla; Jr, ; Jeffrey Keith, Moore; Gary L., Waterman; George Joji, Murakawa; Scott Alfred, Fretzin; Ellen H., Frankel; Sunil Sharan, Dhawan; Lucyna, Leszniewska; Maria, Poznanska; Anna Sobieszek, Kundro; Grazyna M., Chodorowska; Katarzyna Turek, Urasinska; Romuald, Maleszka; Andrzej, Kaszuba; Lidia, Rajzer; Elizbieta Barbara, Szymanska; Lidia, Rudnicka; Neil James, Korman; Jamie Debra, Weisman; Artis P., Truett; Jeffry, Jacqmein; Steven Robert, Cohen; Gary L., Heller; Peter J., Jenkin; Abe, Marcadis; George Sorin, Tiplica; Anca Aghinitei Zbranca, Toporas; Simona Laura, Ianosi; Ion, Florea; Claus, Zachariae; Lars, Iversen; Annalisa, Patrizi; Romanelli, Marco; Christopher, Griffiths; John Berth, Jones; John, Foerster; Ronald C., Savin; Christopher G., Nelson; Lyn Carol Chamberlain, Guenther; Lorne E., Albrecht; Chih ho H., Hong; Arnon, Katz; Mani, Raman; David N., Adam; Aamir, Butt; Stephen Peter, Shumack; Kurt Aaron Josef, Gebauer; Lynda Jane, Spelman; Shireen Kaur, Sidhu; Michael George, Freeman; Peter Anthony, Foley; Lajos, Kemeny; Eva, Remenyik; Zsuzsanna, Karolyi; Marc, Bourcier; Wayne Douglas, Carey; Victoria, Taraska; Derek, Haaland; Aditya Kumar, Gupta; Catherine, Maari; Darryl Paul, Toth; Chih ho H., Hong; Lorne E., Albrecht; Michael, Sebastian; Sandra, Philipp; Roland, Kaufmann; Diamant, Thaci; Thomas Andreas, Werfel; Leila, Parise; Ingo, Haase; Petra Staubach, Renz; Shinichi, Imafuku; Juichiro, Nakayama; Tadashi, Terui; Hideki, Nakajima; Shigetoshi, Sano; Uncover, 2 Study Group; Uncover, 3 Study Group
File in questo prodotto:
File Dimensione Formato  
nejmoa1512711-1.pdf

accesso aperto

Tipologia: Versione finale editoriale
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 309.19 kB
Formato Adobe PDF
309.19 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11568/832725
Citazioni
  • ???jsp.display-item.citation.pmc??? 235
  • Scopus 610
  • ???jsp.display-item.citation.isi??? 579
social impact